Skip to main content

Rockpointe

Events
Courses
Search
Cart 0
Sign Up
Sign In

Item Added to Cart

You just added

You have item(s) in your cart

  • Proceed to Checkout
  1. Courses
  2. Pustular Psoriasis: Recogni...

Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease


A CME/ABIM MOC/ABD MOC Activity

TO REGISTER
Click here to complete your registration.


If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

DATE AND TIME

AGENDA
Welcome and Introduction
Diagnosing and Assessing Severity of Pustular Psoriasis
Managing Pustular Psoriasis
Q&A Session and Activity Roundup

PROGRAM DESCRIPTION
Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

Current systemic treatment has involved cyclosporine, methotrexate or acitretin. The Japanese Dermatological Association has also published guidelines that include a treatment algorithm. However, it has been recognized that IL-36 cytokines are likely the key driver of the autoimmune response in pustular psoriasis. There are two novel, investigational monoclonal antibodies that target the IL-36 receptor. In addition, agents that target other molecules have also been investigated.

Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease will review the most recent guidelines for diagnosing, classifying, and assessing the severity of pustular psoriasis and provide information on current treatment guidelines and agents in development to manage this rare group of disorders.

STEERING COMMITTEE
Alice B. Gottlieb, MD, PhD
Clinical Professor of Dermatology, Department of Dermatology
Division of Rheumatology
Icahn School of Medicine at Mount Sinai
Medical Director, Department of Dermatology
                           Mount Sinai at Union Square
                           New York, NY

Abby S. Van Voorhees, MD
Professor and Chair, Department of Dermatology
Eastern Virginia Medical School
Norfolk, VA


TARGET AUDIENCE

The intended audience for this educational initiative is dermatologists, the clinicians who manage patients with pustular psoriasis.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Discuss how the pathophysiology of pustular psoriasis differs from that of plaque psoriasis
  • Employ the most recent consensus recommendations to diagnose and classify pustular psoriasis
  • Apply the most recent guidelines when managing patients with pustular psoriasis
  • Assess the mechanism of action, efficacy, and safety of agents in development for managing pustular psoriasis
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

AMERICAN BOARD OF DERMATOLOGY MOC INFORMATION
Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 Credits™ annually. Half of these credits must be Dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified dermatologists in contributing towards this MOC requirement set forth by the ABD.


DISCLOSURE INFORMATION
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

Disclosures will be made known to the participants prior to the start of the activity.

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SYSTEM CHECK
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

HARDWARE REQUIREMENTS
WINDOWS

  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
MAC OS
  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
MOBILE
  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later
SOFTWARE REQUIREMENTS
DSL/cable (wired connection recommended)

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe


In collaboration with


This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

PCME Privacy Policy

Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease

Tue, May 11, 2021 @ 6:00 PM EDT

Post-Test: Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease

Assessment: 4 questions 5 retakes

Evaluation: Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease

Survey: 27 questions

Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease, MD/MOC

Certificate: 0/3 Course items completed

Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease, Non-MD

Certificate: 0/3 Course items completed
  • Events
  • Courses
  • Search
  • Support
  • Sign Up
  • Sign In
  • Privacy Policy | Cookies Policy